脉血康胶囊联合尿激酶治疗下肢深静脉血栓的临床研究  

Clinical study on Maixuekang Capsules combined with urokinase in treatment of lower extremity deep venous thrombosis

作　　者：代朋许 张克林 石琳 白建民[4] 苏冉 DAI Peng-xu;ZHANG Ke-lin;SHI Lin;BAI Jian-min;SU Ran(Department of Emergency,Pingdingshan the Second People's Hospital,Pingdingshan 467000,China;Department of Invasive Technology,Pingdingshan the Second People's Hospital,Pingdingshan 467000,China;Department of Nephrology,Pingdingshan the Second People's Hospital,Pingdingshan 467000,China;Department of Clinical Medicine,Nanyang Medical College,Nanyang 473000,China;Western Medicine Pharmacy,The First Affiliated Hospital of Zhengzhou University,Zhengzhou 450000,China)

机构地区：[1]平顶山市第二人民医院急诊科,河南平顶山467000 [2]平顶山市第二人民医院介入科,河南平顶山467000 [3]平顶山市第二人民医院肾病科,河南平顶山467000 [4]南阳医学高等专科学校临床医学系,河南南阳473000 [5]郑州大学第一附属医院西药房,河南郑州450000

出　　处：《现代药物与临床》2021年第12期2564-2568,共5页Drugs & Clinic

基　　金：河南省社科联、河南省经团联调研课题(SKL-2018-497)。

摘　　要：目的探讨脉血康胶囊联合注射用尿激酶治疗下肢深静脉血栓的临床疗效。方法选取2019年9月—2021年7月在平顶山市第二人民医院就诊的91例下肢深静脉血栓患者,根据随机数字表法将所有患者分为对照组(45例)和治疗组(46例)。对照组患者于患肢足背静脉微量泵入注射用尿激酶,30万单位加入生理盐水500 mL中充分稀释,1次/d。治疗组在对照组基础上口服脉血康胶囊,1.0 g/次,3次/d。两组患者连续治疗2周。观察两组临床疗效,比较两组患者治疗前后周径差、疼痛程度、血流参数、血清炎症因子水平。结果治疗后,治疗组的总有效率(89.13%)明显高于对照组的总有效率(71.11%)(P<0.05)。治疗后,两组周径差、视觉模拟评分法(VAS)显著降低(P<0.05),治疗组周径差、VAS评分较对照组降低更明显(P<0.05)。治疗后,两组的凝血时间(K值)、反应时间(R值)明显升高,最大振幅(MA)显著降低(P<0.05);治疗组的K值、R值高于对照组,MA低于对照组(P<0.05)。治疗后,两组的白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)、白细胞介素-8(IL-8)水平显著降低(P<0.05);治疗组的IL-6、TNF-α、IL-8水平比对照组低(P<0.05)。结论脉血康胶囊联合注射用尿激酶治疗下肢深静脉血栓的临床疗效确切,能有效减轻水肿和疼痛程度,改善患肢的血液循环,调节血清IL-6、TNF-α、IL-8水平,安全性较好。Objective To investigate the clinical efficacy of Maixuekang Capsules combined with Urokinase for injection in treatment of lower extremity deep venous thrombosis. Methods Patients(91 cases) with lower extremity deep venous thrombosis in Pingdingshan the Second People’s Hospital from September 2019 to July 2021 were randomly divided into the control group(45 cases)and the treatment group(46 cases). Patients in the control group were micro-pumped Urokinase for injection into the dorsal vein of the affected limb, 300 000 units fully diluted in 500 mL normal saline, once daily. Patients in the treatment group were po administered with Maixuekang Capsules on the basis of the control group, 1.0 g/time, three times daily. Patients in two groups were treated for 2 weeks. After treatment, the clinical efficacies were evaluated, and peripheral diameter difference, pain degree, blood flow parameters,the levels of inflammatory factors in two groups were compared. Results After treatment, the total effective rate of the treatment group(89.13%) was significantly higher than that of the control group(71.11%)(P < 0.05). After treatment, the peripheral diameter difference and VAS score of two groups were significantly decreased(P < 0.05), and after treatment, the peripheral diameter difference and VAS score of the treatment group were significantly lower than those of the control group(P < 0.05). After treatment, the K value and R value in two groups were significantly increased, but the MA in two groups were significantly decreased(P < 0.05). After treatment,the K value and R value of the treatment group were higher than those of the control group, but the MA of the treatment group was lower than that of the control group(P < 0.05). After treatment, the levels of IL-6, TNF-α, and IL-8 in two groups were significantly decreased(P < 0.05). The levels of IL-6, TNF-α, and IL-8 in the treatment group were lower than those in the control group(P < 0.05).Conclusion Maixuekang Capsules combined with Urokinase for injection is effec

关 键 词：脉血康胶囊 注射用尿激酶 下肢深静脉血栓 周径差 疼痛程度 血流参数 炎症因子 

分 类 号：R973[医药卫生—药品]